Silencing TPH1 expression slowed down tumor growth in an established mouse model, whereas treatment with TPH1 inhibitor alleviated tumor progression in an azoxymethane/dextran sodium sulphate (AOM/DSS)-induced colorectal cancer (CRC) mouse model. This evidence concerns the gene TPH1 and colorectal carcinoma.